Palatin Technologies, Inc. Reports Fiscal Year 2008 Second Quarter Results; Teleconference and Webcast to be held on Februar...( CRANBURY N.J. Feb. 11 /- Palatin ...),Health

CRANBURY, N.J., Feb. 11 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (Amex: PTN) announced today financial results for the second quarter ended December 31, 2007. Palatin reported a net loss of $3.8 million, or ($0.04) per basic and diluted share, for the quarter ended December 31, 2007, compared to a net loss of $6.5 million, or ($0.09) per basic and diluted share, for the same period in 2006. Total revenues for the quarter ended December 31, 2007 were $743,000, compared to $3.7 million for the same period in 2006. As of December 31, 2007, the Company had cash, cash equivalents and investments totaling $22.8 million.

The decrease in the net loss for the quarter ended December 31, 2007 compared to the quarter ended December 31, 2006 was primarily attributable to the reduction in research and development expenses related to bremelanotide, the Company's drug under development for the treatment of erectile dysfunction and female sexual dysfunction.

LICENSES, GRANTS AND CONTRACTS

For the quarter ended December 31, 2007, Palatin recognized $0.7 million of contract revenue related to its collaboration agreement with AstraZeneca AB. In the comparable quarter of 2006, Palatin recognized $3.7 million of contract revenue, primarily related to the reimbursement by King Pharmaceuticals, Inc. of bremelanotide-related development costs pursuant to the companies' collaboration agreement, which was terminated by King in the quarter ended September 30, 2007.

COSTS AND EXPENSES

Total operating expenses for the quarter ended December 31, 2007 were $6.1 million, compared to $11.2 million for the comparable quarter of 2006, reflecting lower development costs of bremelanotide which were partially offset by an increase
'/>"/>